Drug Pipeline

Repotrectinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
5
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-05-20 NCT07599007 Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small… Not Yet Recruiting
Active Studies by Phase
Phase 2
2
Phase 1/2
2
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06315010 REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain… NSCLC Recruiting
NCT06552234 Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With… NSCLC Stage IV Recruiting
Phase 1/2
NCT03093116 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK… Locally Advanced Solid Tumors Recruiting
NCT05004116 A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults… Advanced Cancer Recruiting
Not specified
NCT07599007 Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small… Non-Small Cell Lung Cancer Not Yet Recruiting
Sponsors Running Repotrectinib Trials
Turning Point Therapeutics, Inc. (1) Memorial Sloan Kettering Cancer Center (1) MedSIR (1) Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (1) Bristol-Myers Squibb (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (1)
Get alerts when Repotrectinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free